CytoDyn (CytoDyn) Interest Coverage : 0 (At Loss) (As of Feb. 2024)

View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. CytoDyn's Operating Income for the three months ended in Feb. 2024 was $-3.41 Mil. CytoDyn's Interest Expense for the three months ended in Feb. 2024 was $-1.56 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for CytoDyn's Interest Coverage or its related term are showing as below:

CYDY's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.11
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CytoDyn Interest Coverage Historical Data

The historical data trend for CytoDyn's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CytoDyn Interest Coverage Chart

CytoDyn Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Interest Coverage

Get a 7-Day Free Trial

CytoDyn Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Interest Coverage	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of CytoDyn's Interest Coverage

For the Biotechnology subindustry, CytoDyn's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoDyn's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Interest Coverage distribution charts can be found below:

* The bar in red indicates where CytoDyn's Interest Coverage falls into.

CytoDyn Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CytoDyn's Interest Coverage for the fiscal year that ended in May. 2023 is calculated as

Here, for the fiscal year that ended in May. 2023, CytoDyn's Interest Expense was $-6.75 Mil. Its Operating Income was $-40.58 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.00 Mil.

CytoDyn did not have earnings to cover the interest expense.

CytoDyn's Interest Coverage for the quarter that ended in Feb. 2024 is calculated as

Here, for the three months ended in Feb. 2024, CytoDyn's Interest Expense was $-1.56 Mil. Its Operating Income was $-3.41 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.18 Mil.

CytoDyn did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

CytoDyn (OTCPK:CYDY) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

CytoDyn Interest Coverage Related Terms

Thank you for viewing the detailed overview of CytoDyn's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn (CytoDyn) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

296:Germany

Address

1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website

https://www.cytodyn.com

CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

Executives

Tyler Blok	officer: EVP of Legal Affairs	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes	director
Ryan Dunlap	director	310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman	officer: President	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese	officer: Chief Financial Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor	officer: Chief Operating Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland	officer: CFO, Treasurer and Secretary	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660